Personalized Anemia Treatment Systems

A next-generation anemia treatment system that integrates wearable devices, genomic analysis, and machine learning to provide personalized treatment regimens, enhancing efficacy and reducing side effects.

The original patent disclosed the use of HIF prolyl hydroxylase inhibitors for treating anemia. However, the treatment outcomes were variable, and the inhibitors' efficacy was limited by their systemic administration and lack of personalized dosing. The new inventive concept addresses these limitations by introducing a wearable device that administers the inhibitor in a controlled release profile synchronized with the patient's circadian rhythm, ensuring optimal efficacy and minimal side effects.

The inventive concept comprises a wearable device that administers a HIF prolyl hydroxylase inhibitor in a controlled release profile, which is synchronized with the patient's circadian rhythm using machine learning algorithms. The device is integrated with a genomic analysis system that identifies genetic markers associated with inhibitor responsiveness, allowing for personalized treatment dosages. Additionally, the system includes a non-invasive sensor that monitors hemoglobin and EPO serum levels in real-time, providing personalized treatment recommendations. The system's efficacy is further optimized through the use of machine learning algorithms that analyze large datasets of patient responses to HIF prolyl hydroxylase inhibitors.

The new claims introduce a paradigm shift in anemia treatment by integrating wearable devices, genomic analysis, and machine learning to provide personalized treatment regimens. The controlled release profile synchronized with the patient's circadian rhythm, the genomic analysis-based dosing, and the real-time monitoring and optimization of treatment efficacy are all novel and non-obvious features that distinguish the new inventive concept from the original patent.

Alternative embodiments of the inventive concept could include the use of different types of wearable devices, such as implantable or injectable devices, or the integration of additional sensors to monitor other physiological parameters. The system could also be adapted for use in treating other diseases or conditions, such as cancer or cardiovascular disease.

The personalized anemia treatment system has significant commercial potential in the pharmaceutical and medical device industries, particularly in the context of precision medicine. The system's ability to provide personalized treatment regimens and optimize treatment efficacy could lead to improved patient outcomes, reduced healthcare costs, and increased market share for companies that adopt this technology.